Immunotherapy of Lymphoma

Ronald Levy, MD

Robert K. Summy and Helen K. Summy Professor of Medicine
Chief, Division of Oncology, Stanford University

Review of the Development of Monoclonal Antibodies and an Update on the Attempt To Develop Therapeutic Vaccines

Thursday, June 18, 2009

Webcast

Watch a video of the lecture.
(Microsoft Windows Media)

Dr. Levy’s research concentrates on malignant lymphoma, the cancer of the immune system. He employs the tools of immunology and molecular biology to understand andto treat this disease. In 1981 he was the first to successfully treat a cancer patient with a monoclonal antibody. He went on to develop rituximab (Rituxan®), now a standard treatment for lymphoma that is extending the lives of patients worldwide. He is currently conducting clinical trials to induce immune responses by lymphoma patients against their own tumors.

Dr. Levy’s work spans the entire gamut of translational science, from discovery to preclinical development to clinical trials in patients. He is an elected member of the National Academy of Sciences and the Institute of Medicine. In 1982 he received the first Armand Hammer Award for Cancer Research, and later received the Karnofsky Award from the American Society of Clinical Oncology, the Burchenal Award from the American Association of Cancer Research, the Kettering Prize from the General Motors Cancer Research Foundation, the Medal of Honor by the American Cancer Society, the Damashek Prize from the American Society of Hematology and the King Faisal International Prize.

For more information contact:
Institutional Advancement, 215-728-2873

Download the Lecture Poster Here: PDF File of Poster Suitable for Printing (1.6MB, Requires Adobe Acrobat Reader)